Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 6
2006 1
2008 1
2009 1
2010 1
2011 1
2013 1
2015 4
2016 3
2017 4
2018 1
2019 1
2020 1
2021 1
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH; ACT IV trial investigators. Weller M, et al. Among authors: recht ld. Lancet Oncol. 2017 Oct;18(10):1373-1385. doi: 10.1016/S1470-2045(17)30517-X. Epub 2017 Aug 23. Lancet Oncol. 2017. PMID: 28844499 Free article. Clinical Trial.
Patterns of Progression in Patients With Newly Diagnosed Glioblastoma Treated With 5-mm Margins in a Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With Concurrent and Adjuvant Temozolomide.
Mendoza MG, Azoulay M, Chang SD, Gibbs IC, Hancock SL, Pollom EL, Adler JR, Harraher C, Li G, Gephart MH, Nagpal S, Thomas RP, Recht LD, Jacobs LR, Modlin LA, Wynne J, Seiger K, Fujimoto D, Usoz M, von Eyben R, Choi CYH, Soltys SG. Mendoza MG, et al. Among authors: recht ld. Pract Radiat Oncol. 2023 May-Jun;13(3):e239-e245. doi: 10.1016/j.prro.2023.01.008. Epub 2023 Feb 2. Pract Radiat Oncol. 2023. PMID: 36736621 Clinical Trial.
Development of [18F]DASA-10 for enhanced imaging of pyruvate kinase M2.
Kendirli MT, Malek R, Silveira MB, Acosta C, Zhang S, Azevedo C, Nagy SC, Habte F, James ML, Recht LD, Beinat C. Kendirli MT, et al. Among authors: recht ld. Nucl Med Biol. 2023 Sep-Oct;124-125:108382. doi: 10.1016/j.nucmedbio.2023.108382. Epub 2023 Aug 22. Nucl Med Biol. 2023. PMID: 37634399
First-in-human intraoperative near-infrared fluorescence imaging of glioblastoma using cetuximab-IRDye800.
Miller SE, Tummers WS, Teraphongphom N, van den Berg NS, Hasan A, Ertsey RD, Nagpal S, Recht LD, Plowey ED, Vogel H, Harsh GR, Grant GA, Li GH, Rosenthal EL. Miller SE, et al. Among authors: recht ld. J Neurooncol. 2018 Aug;139(1):135-143. doi: 10.1007/s11060-018-2854-0. Epub 2018 Apr 6. J Neurooncol. 2018. PMID: 29623552 Free PMC article. Clinical Trial.
A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2-Induced Glycolytic Reprogramming in Glioblastoma.
Beinat C, Patel CB, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, Iagaru A, Davidzon G, Thomas R, Nagpal S, Recht LD, Gambhir SS. Beinat C, et al. Among authors: recht ld. Clin Cancer Res. 2021 Dec 1;27(23):6467-6478. doi: 10.1158/1078-0432.CCR-21-0544. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475101 Free PMC article.
Inflammatory Pseudotumors of the Skull Base: Meta-Analysis.
Alyono JC, Shi Y, Berry GJ, Recht LD, Harsh GR 4th, Jackler RK, Corrales CE. Alyono JC, et al. Among authors: recht ld. Otol Neurotol. 2015 Sep;36(8):1432-8. doi: 10.1097/MAO.0000000000000818. Otol Neurotol. 2015. PMID: 26164448
Correction: Macrophage Exclusion after Radiation Therapy (MERT): A First-in-Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma.
Thomas RP, Nagpal S, Iv M, Soltys SG, Bertrand S, Pelpola JS, Ball R, Yang J, Sundaram V, Chernikova SB, Lavezo J, Born D, Vogel H, Brown JM, Recht LD. Thomas RP, et al. Among authors: recht ld. Clin Cancer Res. 2023 Jan 17;29(2):502. doi: 10.1158/1078-0432.CCR-22-3712. Clin Cancer Res. 2023. PMID: 36647675 No abstract available.
33 results